Table 3.
Bone Mass and Cortical and Trabecular Microarchitecture in OVX β-Arrestin2−/− Mice
|
WT |
β-arrestin2−/− |
|||
| Sham (n = 8) | OVX (n = 7) | Sham (n = 8) | OVX (n = 9) | |
| BMD change (%) | ||||
| Total body | 3.4 ± 1.5 | −0.8 ± 1.1 | 4.6 ± 2.2 | −1.3 ± 1.4* |
| Lumbar spine | 3.3 ± 2.2 | −13.1 ± 2.9† | 2.7 ± 6.7 | −9.0 ± 2.3 |
| Femoral shaft | 11.0 ± 3.4 | 1.5 ± 3.4 | 7.5 ± 1.5 | 2.8 ± 2.2 |
| Vertebral trabecular bone | ||||
| BV/TV (%) | 25.4 ± 0.9 | 23.0 ± 1.3 | 27.0 ± 1.6 | 20.7 ± 1.6* |
| TbTh (μm) | 57.29 ± 1.19 | 53.47 ± 1.01* | 63.6 ± 1.82# | 55.11 ± 2.12* |
| TbN (/mm) | 4.19 ± 0.11 | 4.05 ± 0.10 | 4.07 ± 0.12 | 3.72 ± 0.10*‡ |
| TbSp (μm) | 236.9 ± 7.2 | 246.6 ± 6.6 | 238.5 ± 7.0 | 267.2 ± 7.9* |
| Distal femur trabecular bone | ||||
| BV/TV (%) | 5.17 ± 0.44 | 4.09 ± 0.59 | 4.51 ± 0.40 | 3.00 ± 0.53* |
| TbTh (μm) | 44.78 ± 1.13 | 40.17 ± 1.50* | 45.76 ± 1.18 | 43.96 ± 2.49 |
| TbN (/mm) | 3.19 ± 0.10 | 3.01 ± 0.11 | 3.00 ± 0.13 | 2.31 ± 0.16*§ |
| TbSp (μm) | 312.1 ± 10.6 | 335.5 ± 14.0 | 339.4 ± 19.0 | 462.2 ± 48.4*‡ |
| Cortical bone (diaphysis) | ||||
| Total area (mm2) | 1.62 ± 0.04 | 1.64 ± 0.04 | 1.56 ± 0.03 | 1.56 ± 0.03 |
| Bone area (mm2) | 0.79 ± 0.02 | 0.77 ± 0.01 | 0.78 ± 0.02 | 0.74 ± 0.01 |
| Medullary area (mm2) | 0.83 ± 0.03 | 0.88 ± 0.03 | 0.78 ± 0.02 | 0.82 ± 0.02 |
| BA/TA (%) | 48.8 ± 0.5 | 46.7 ± 0.6* | 49.8 ± 0.7 | 47.5 ± 0.4* |
| Cortical thickness (μm) | 200 ± 2 | 193 ± 2* | 203 ± 4 | 191 ± 2* |
* p < 0.05 and † p < 0.005 vs. Sham within genotype.
‡ p < 0.05 and § p < 0.005 vs. WT within treatment group.
BV/TV, bone volume fraction; TbN, trabecular number; TbTh, trabecular thickness; TbSp, trabecular separation; BA/TA, bone area fraction.